<?xml version="1.0" encoding="UTF-8"?>
<p>NEPA was developed as an oral fixed combination of the highly selective NK
 <sub>1</sub>RA, netupitant (300 mg), and the clinically [
 <xref rid="mdx698-B4" ref-type="bibr">4</xref>] and pharmacologically [
 <xref rid="mdx698-B11" ref-type="bibr">11</xref>] distinct 5-HT
 <sub>3</sub>RA, palonosetron (0.5 mg). The simultaneous targeting of two critical antiemetic pathways, in unison with the single dose administration results in a convenient antiemetic offering long-lasting protection from CINV.
</p>
